Lexicon Presents Positive Data from Telotristat Etiprate Study

A pen and a pair of glasses on top of a graph
Credit: Shutterstock photo

Lexicon Pharmaceuticals, Inc.'sLXRX has announced positive data on its prime candidate, telotristat etiprate, from a phase III study, TELESTAR.

The double-blind phase III study evaluated two doses of oral telotristat etiprate, 250 mg and 500 mg, each taken thrice daily versus placebo over a 12-week period in patients suffering from carcinoid syndrome that was not adequately controlled by a long-acting somatostatin analog (SSA) therapy.

Data from the study showed that patients, who added telotristat etiprate to their SSA therapy at both the evaluated doses, experienced a statistically significant reduction in the average number of daily bowel movements from baseline compared to placebo. Consequently, the study met its primary endpoint.

Data from the studies also showed that patients, who received telotristat etiprate, experienced a lower frequency of flushing episodes and less intense abdominal pain compared to the placebo arm.

We note that telotristat etiprate enjoys orphan drug status and fast track status in the U.S. The successful development and commercialization of the candidate will be a significant boost for Lexicon as it does not have any approved products in its kitty yet.

We note that Lexicon has a commercialization agreement with Ipsen for telotristat etiprate. While Lexicon has rights to market telotristat etiprate (upon approval) in the U.S. and Japan, Ipsen will commercialize it in Europe and other countries outside the U.S. as well as Japan.

Lexicon carries a Zacks Rank #3 (Hold). Some better-ranked stocks in the health care sector are Anika Therapeutics Inc. ANIK , Avalanche Biotechnologies, Inc. AAVL and Acceleron Pharma, Inc. XLRN . All three carry a Zacks Rank #2 (Buy).

Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report

LEXICON PHARMA (LXRX): Free Stock Analysis Report

ANIKA THERAPEUT (ANIK): Free Stock Analysis Report

ACCELERON PHARM (XLRN): Free Stock Analysis Report

AVALANCHE BIOT (AAVL): Free Stock Analysis Report

To read this article on click here.

Zacks Investment Research

The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.

The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.

In This Story


Other Topics


Latest Markets Videos


    Zacks is the leading investment research firm focusing on stock research, analysis and recommendations. In 1978, our founder discovered the power of earnings estimate revisions to enable profitable investment decisions. Today, that discovery is still the heart of the Zacks Rank. A wealth of resources for individual investors is available at

    Learn More